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Abstract
Background: Few data are available regarding the treatment of metastatic colorectal cancer elderly patients with
anti-EGFR agents in combination with chemotherapy. FOLFOX plus panitumumab is a standard first-line option for
RAS wild-type metastatic colorectal cancer. Slight adjustments in chemo-dosage are commonly applied in clinical
practice to elderly patients, but those modified schedules have never been prospectively tested. Clinical definition
of elderly (≥70 years old) patients that may deserve a more or less intensive combination therapy is still debated.
Several geriatric screening tools have been developed to predict survival and risk of toxicity from treatment. Among
those, the G8 screening tool has been tested in cancer patients showing the strongest prognostic value for overall
survival, while the CRASH score can stratify patients according to an estimated risk of treatment-related toxicities.
Methods: The PANDA study is a prospective, open-label, multicenter, randomized phase II trial of first-line therapy with
panitumumab in combination with dose-adjusted FOLFOX or with 5-fluorouracil monotherapy, in previously untreated
elderly patients (≥70 years) with RAS and BRAF wild-type unresectable metastatic colorectal cancer. RAS and BRAF analyses
are centralized. Geriatric assessment by means of G8 and CRASH score is planned at baseline and G8 will be re-evaluated
at disease progression. The primary endpoint is duration of progression-free survival in both arms. Secondary endpoints
include prospective evaluation of the prognostic role of G8 score and the correlation of CRASH risk categories with
toxicity.
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Discussion: The PANDA study aims at exploring safety and efficacy of panitumumab in combination with FOLFOX or
with 5FU/LV in elderly patients affected by RAS and BRAF wild-type metastatic colorectal cancer, to identify the most
promising treatment strategy in this setting. Additionally, this is the first trial in which the prognostic role of the G8
score will be prospectively evaluated. Results of this study will drive further experimental developments for one or both
combinations.
Trial Registration: PANDA is registered at Clinicaltrials.gov: NCT02904031, July 11, 2016. PANDA is registered at
EudraCT-No.: 2015–003888-10, September 3, 2015.
Keywords: Elderly, Metastatic colorectal cancer, RAS, BRAF, Panitumumab, G8, CRASH, Clinical trial
Background
Aging population is highly represented among metastatic
colorectal cancer (mCRC) patients [1]. However, the
therapeutic decision making in patients older than 70 years
of age is still a debated issue due to the paucity of trial-
based recommendations.
The clinical definition of elderly (over 70 years) CRC
patients that may deserve a more or less intensive com-
bination therapy is still debated. A reasonable approach
for defining candidates to different treatment intensity is,
in this setting, to consider a cut-off of 75 years old com-
bined with Eastern Cooperative Oncology Group – per-
formance status (ECOG PS) assessment, in order to
discriminate patients eligible to combination therapies
from patients eligible to less intensive treatment.
In the daily clinical practice, treatment choices are mainly
driven by data from retrospective studies, post-hoc or
pooled analyses of randomized clinical trials or meta-
analyses. However, those results do not necessarily reflect
the general mCRC population and are often limited by
potential confounding factors [2, 3]. Thus, an individualized
treatment approach is usually adopted in this setting, after
an in-depth evaluation of biological age, performance
status, comorbidities, polypharmacy, social support, global
functioning and cognitive abilities, and consequently the
risk of experiencing adverse events and decreased quality of
life [4].
Currently, in elderly patients, fluoropyrimide-based
monotherapy plus bevacizumab, irrespectively of the mo-
lecular status of RAS (Rat sarcoma viral oncogene homo-
log), is a reasonable upfront treatment based on the result
of the phase III open-label AVEX trial. Patients aged
≥70 years were randomized to receive capecitabine with
or without bevacizumab. Among 280 randomized pa-
tients, the addition of bevacizumab improved progression
free survival (PFS), the primary endpoint (9.1 versus
5.1 months; Hazard Ratio (HR) 0.53, 95% Confidence
Interval (CI) 0.41–0.69; p < 0.0001), as well as the overall
response rate (ORR) (19% versus 10%; p = 0.04); the differ-
ence in overall survival (OS), a secondary end point, was
not statistically significant (20.7 months versus
16.8 months; HR 0.79, 95% CI 0.57–1.09; p = 0.18) [5].
Data regarding the adoption of a doublet chemother-
apy regimen derive from the MRC FOCUS2 and the
FFCD 2001–2002 studies [6, 7].
The MRC FOCUS2 was the first randomized clinical
trial conducted specifically among elderly and frail
untreated mCRC patients, considered unfit for full-dose
chemotherapy, with the aim to investigate reduced-dose
chemotherapy options. Patients (n = 459; 22% < 70 years;
35% 70–75 years, and 43% > 75 years) was randomized to
receive treatment with 5-fluorouracil (5-FU)/leucovorin
(LV), simplified FOLFOX (folinic-acid, 5-FU, oxaliplatin),
capecitabine, or CAPOX/XELOX (capecitabine,
oxaliplatin), at 80% of the standard drug doses. The
addition of oxaliplatin versus no oxaliplatin resulted in a
non-statistically significant trend toward improvement in
PFS (median 5.8 versus 4.5 months; HR 0.84, 95% CI:
0.69–1.01, p = 0.07), an improvement in overall response
rate (ORR: 13% versus 35%; p < 0.001) with a lack of bene-
fit in OS. No significant differences in adverse events were
observed in patients receiving the combination treatment
compared to those receiving a monotherapy. Overall, the
MRC FOCUS2 data showed that the addition of reduced-
dose oxaliplatin to fluoropyrimidine-based therapy is
feasible [6].
The adoption of an irinotecan-based first-line chemo-
therapy in mCRC patients ≥75 years was evaluated in
the phase III FFCD 2001–2002 study. Among 282 ran-
domized patients, those receiving irinotecan plus 5FU/
LV showed a significant benefit, over those who received
5-FU/LV alone, in terms of ORR (46.3% versus 27.4%;
OR 2.3, 95% CI: 1.4–3.8, p = 0.001), a non-significant
benefit in terms of PFS (7.3 versus 5.2 months; HR 0.84,
95% CI: 0.66–1.07, p = 0.15), and no benefit in terms of
OS. Of note, geriatric screening tools were adopted to
perform prognostic factor analyses for treatment safety
and baseline decrements in cognitive function and In-
strumental Activities of Daily Living (IADLs) predicted
for grade 3 to 4 toxicity and risk for hospitalization [7].
Epidermal growth factor receptor (EGFR) signalling
plays a key role in CRC development and EGFR inhibi-
tors (cetuximab and panitumumab) are well established
therapeutic agents in mCRC treatment [8, 9]. From early
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evidence of a potential subgroup effect in anti-EGFRs
activity to post-hoc analyses of randomized trials, Kirsten
rat sarcoma (KRAS) exon 2 and subsequently KRAS
exons 3 and 4 and NRAS exon 2, 3 and 4 mutations have
been identified as negative predictive biomarkers for
anti-EGFRs activity. Currently, every patient considered
for an anti-EGFR therapy must undergo an extended
RAS mutational testing, including KRAS and NRAS co-
dons 12, 13 of exon 2; 59, 61 of exon 3; and 117 and 146
of exon 4. Anti-EGFRs treatment is restricted to all RAS
wild-type patients [10]. However, despite being molecu-
larly selected according to regulatory guidelines, several
patients with a RAS wild-type mCRC do not benefit
from anti-EGFR agents, implying that other mutations/
mechanisms of resistance can have an impact on anti-
EGFRs activity. V-Raf murine sarcoma viral oncogene
homolog B1 (BRAF) V600E mutation is one of these, and
available data support the use of BRAF as a negative pre-
dictive biomarker in clinical practice [11–13].
Although FOLFOX plus panitumumab is a standard
first-line therapy option for RAS wild-type untreated mCRC
patients [14], data on the adoption of anti-EGFRs in elderly
mCRC patients are scarce and mostly derived from retro-
spective or small prospective studies of molecularly unse-
lected patients. Slight adjustments in chemo-dosage are
commonly applied in routinely practice to elderly patients,
but those modified schedules have never been prospectively
tested.
In the subgroup analysis of RAS wild-type patients
from PRIME study the addition of panitumumab to the
first-line FOLFOX-4 showed a benefit over FOLFOX-4
in the subset of patients aged more than 65 years (n =
188), in terms of OS (26.6 versus 17.4 months; HR 0.78,
95% CI 0.58–1.09), PFS (9.7 versus 9.2 months; HR 0.88,
95% CI 0.65–1.19) and ORR (49% versus 42%) and did
not raise any safety concerns. Although the numbers are
small, these data support the fact that there is no evi-
dence of a negative interaction between age and treat-
ment efficacy. The analysis, however, was conducted
with an age cut-off of 65 years while the analysis of effi-
cacy in the > 75 years population was limited by patient
numbers (n = 34) to draw conclusions [15], leaving the
question of combined treatment plus panitumumab in
properly-defined elderly patients still open.
Similarly, in a small phase II trial, enrolling elderly (age ≥
70 years) patients considered not candidates for chemother-
apy, in the RAS wild-type subgroup (n = 15), the first-line
monotherapy with panitumumab seemed to be effective
(overall response rate 13.3%, median PFS: 7.9 months; me-
dian OS: 12.3 months) and well-tolerated [16]. Encouraging
data were also reported in another study investigating pani-
tumumab monotherapy in molecularly selected RAS and
BRAF wild-type frail elderly patients deemed unfit for
chemotherapy or irinotecan-based doublets [17].
It is crucial, thus, to prospectively explore the efficacy of
different chemotherapy backbones in combination with
panitumumab as first-line treatment in this setting of
mCRC patients. Moreover, RAS and BRAF testing should
be definitively proven as clinically useful in frail/very eld-
erly patients, as the addition of anti-EGFRs to chemother-
apy could confer a survival advantage and a significant
improvement of quality of life in this subgroup of patients.
Several geriatric assessment methods have been devel-
oped to help driving treatment choices in elderly pa-
tients and to detect disabilities and comorbidities that
may potentially contribute to an older patient’s vulner-
ability predisposing poor outcome and treatment com-
plications. Among them, the G8 screening tool has been
tested in cancer patients showing the strongest prognos-
tic value for overall survival [18–20]; the CRASH score
is able to stratify patients according an estimated risk of
treatment-related toxicities [21].
On the basis of these considerations, we designed the
present randomized phase II trial of first-line therapy
panitumumab in combination with simplified FOLFOX
schedule or with 5-FU/LV alone, in previously untreated
elderly patients with RAS and BRAF wild-type unresect-
able mCRC.
Methods/Design
Aim
The main objective of this trial is to study the efficacy of
panitumumab in combination with FOLFOX and with
5-FU/LV in elderly patients with RAS and BRAF wild-
type mCRC.
Trial design
This is a prospective, open-label, multicenter phase II ran-
domized trial in which initially unresectable and previously
untreated RAS and BRAF wild-type mCRC elderly patients
are randomized to receive FOLFOX plus panitumumab for
up to 12 cycled followed by panitumumab maintenance
until progressive disease (arm A), or 5FU/LV plus panitu-
mumab for up to 12 cycled followed by panitumumab
maintenance (arm B) until progressive disease (Fig. 1). A list
of participating centers is provided in Table 1.
Study endpoints
The primary endpoint is Progression Free Survival defined
as the time from randomization to the first documentation
of objective disease progression or death due to any cause.
Documentation of disease progressive disease is defined as
per Response Evaluation Criteria in Solid Tumors
(RECIST) 1.1 criteria [22] based on investigator assessment.
The secondary endpoints include OS, ORR, early
tumor shrinkage (ETS), R0 Resection Rate, overall
toxicity rate (OTR), Toxicity Rate and geriatric assess-
ment by G8 and by CRASH.
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OS is defined as the time from randomization to the
date of death due to any cause. The objective Response
Rate will be evaluated according to RECIST 1.1 based on
investigator reported measurements.
Early Tumor Shrinkage Rate is defined as the percent-
age of patients, relative to the total of the enrolled subjects
achieving a ≥ 20% decrease in the sum of diameters of
RECIST target lesions at week 8 compared to baseline.
Adverse events are evaluated according to the National
Cancer Institute Common Terminology Criteria for Ad-
verse Events (NCI CTCAE) version 4.0 [23], during the
induction and the maintenance phases of treatment.
Of note, this is the first trial in which the prognostic role
of the G8 score will be prospectively evaluated. The assess-
ment by G8 score is defined as the score resulting from
the G8 screening tool dichotomizing patients in two
groups (score ≤ 14 and > 14). Moreover, the Geriatric
Assessment by CRASH score, defined as the identification
of four categories of different toxicity risk (low, medium-
low, medium-high, high), will be prospectively correlated
with toxicity.
Clinical setting
Metastatic colorectal cancer patients aged ≥70 years are
evaluable for the inclusion in the present study, an
ECOG PS of 1 or 2 is required for patients aged 70 to
75 years, while an ECOG PS of 0 to 1 is required for pa-
tients aged more than 75 years.
Main eligibility criteria include:
 measurable disease according to RECIST version 1.1;
 centrally assessed wild-type RAS and BRAF status of
primary colorectal cancer or related metastasis (see
following paragraph);
 geriatric assessment by G8 screening tool and
CRASH score (see following paragraph);
 adequate bone marrow, liver, and renal function;
 no previous exposure to an oxaliplatin-containing
adjuvant therapy. Previous adjuvant chemotherapy
with fluoropyrimidines alone is allowed if more than
6 months have elapsed between the end of the
adjuvant therapy and disease relapse.
Main exclusion criteria include:
 peripheral neuropathy of grade 1 or higher
according to NCI CTCAE version 4.0;
 contraindications to study drugs.
Each patient’s eligibility is verified by using an
electronic WEB-based system.
Molecular assessment
Molecular testing of RAS and BRAF mutational status
on tumor specimen for each patient is performed as a
screening procedure and centralized at the Department
of Surgical, Medical, Molecular Pathology and Critical
Area, University of Pisa and Unit of Immunology and of
Oncological Molecular Diagnostics, Department of
Oncological Diagnostics, Oncology Institute of Veneto –
IRCCS, Padova, Italy.
KRAS codon 12, 13, 59, 61, 117 and 146 mutations,
NRAS codon 12, 13, 59, 61, 117 and 146 mutations and
BRAF V600E mutation will be assessed by means of
MALDI-TOF MassArray (Sequenom®).
Geriatric assessment
Geriatric assessment by G8 screening tool is performed at
baseline and at the time of disease progression. The G8
screening tool includes seven questions focusing on nutri-
tional status, mobility, neuropsychological problems,
medication use, self-rated health status and age. Each
question provides from 2 to 4 possible answers and a
score is assigned at any type of answer. The sum of the an-
swers scores plus a score based on the age of the patient
will be the final score. It ranges from 0 to 17 (Table 2).
The CRASH screening tool is performed only at baseline
by local investigators according to the online CRASH Score
Calculator developed by Moffit Cancer Center [24]. This
score stratifies patients in four risk categories of severe
hematologic, non-hematologic and combined toxicities.
The hematologic sub-score is calculated by the sum of
scores (ranged from 0 to 2) assigned to the following items:
diastolic blood pressure, IADL, LDH, and MAX2 index.
The non-hematologic score is calculated by the sum of
scores (ranged from 0 to 2) assigned to the following
items: ECOG PS, Mini Mental State Exam (MMSE),
Mini Nutritional Assessment and MAX2 index.
The combined score is calculated by the sum of scores
(ranged from 0 to 2) assigned to the following items:
diastolic blood pressure, IADL, LDH, ECOG PS, MMSE,
MNA and MAX2 index (Table 3).
Fig. 1 Study Design. *Pan = panitumumab
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Table 1 Participating Centers
Principal Investigator Site Name City
Maura Rossi Ospedale SS Antonio e C Arrigo Alessandria
Angela Buonadonna Centro di Riferimento Oncologico Aviano
Nicola Silvestris Istituto Tumori “Giovanni Paolo II” Bari
Fable Zustovich Ospedale San Martino ULSS 1
Dolomiti
Belluno
Ermenegildo Arnoldi ASST Papa Giovanni XXIII Bergamo
Giordano Beretta Humanitas Gavazzeni Bergamo
Claudio Graiff Ospedale di Bolzano. Azienda
Sanitaria dell’Alto Adige
Bolzano
Alberto Zaniboni Fondazione Poliambulanza Istituto
Ospedaliero
Brescia
Saverio Cinieri Ospedale “Senatore A. Perrino” Brindisi
Mario Scartozzi Azienda Ospedaliero Universitaria
di Cagliari Policlinico “Duilio Casula”
Monserrato
Cagliari
Andrea Mambrini A.S.L. 1 Massa Carrara Carrara
Roberto Bordonaro A.R.N.A.S. Garibaldi P.O. Nesima Catania
Alberto Morabito Ospedale Civile Pietro Cosma Cittadella /
Camposampiero
Gianluca Tomasello Istituti Ospitalieri di Cremona Cremona
Cristina Granetto Azienda Sanitaria Ospedaliera
Santa Croce e Carle
Cuneo
Carlo Milandri A.U.S.L. 11 Empoli Empoli
Francesca Vastola Ospedale M. Teresa di Calcutta
ULSS 17
Este/Monselice
Rosa Rita Silva Ospedale E. Profili - Area vasta 2
ASUR
Fabriano
Rodolfo Mattioli Presidio Ospedaliero Santa Croce Fano
Davide Pastorelli Ospedale di Feltre Feltre
Antonio Frassoldati Azienda Ospedaliero Universitaria
Sant’Anna di Ferrara
Ferrara
Lorenzo Antonuzzo Azienda Ospedaliero-Universitaria
Careggi
Firenze
Angela Stefania Ribecco P.O. S. Giovanni di Dio Firenze
Teresa Gamucci Polo Oncologico Provinciale
Frosinone Azienda Sanitaria
Locale
Frosinone
Alberto Ballestrero IRCCS AOU San Martino-IST Genova
Matteo Clavarezza E.O. Ospedali Galliera Genova
Carmelo Bengala A.U.S.L. 9 Grosseto Ospedale
Misericordia
Grosseto
Carlo Aschele Ospedale Sant’Andrea ASL 5
Spezzino
La Spezia
Silvana Leo Ospedale Vito Fazzi Lecce
Antonio Ardizzoia A.O. Provincia di Lecco Lecco
Cecilia Barbara Ospedali Riuniti di Livorno Livorno
Editta Baldini Ospedale San Luca Lucca
Giovanni Luca Frassineti I.R.C.C.S.
Istituto Scientifico
Romagnolo per lo
Studio e la Cura dei
Tumori (I.R.S.T.)
Meldola
Andrea Luciani Azienda Ospedaliera
San Paolo
Milano
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Table 1 Participating Centers (Continued)
Principal Investigator Site Name City
Filippo De Braud Istituto Nazionale dei
Tumori
Milano
Andrea Sartore Bianchi Ospedale Niguarda Milano
Luca Gianni Ospedale San Raffaele Milano
Giorgia Boscolo ULSS 13 Mirano Mirano
Chiara Carlomagno Azienda Ospedaliera
Universitaria Federico II
Napoli
Stefania Gori Ospedale Sacro Cuore
– Don Calabria
Negrar
Sara Lonardi Istituto Oncologico
Veneto I.R.C.C.S.
Padova
Livio Blasi Ospedale “CIVICO - DI
CRISTINA - BENFRATELLI”
Palermo
Silvia Brugnatelli Fondazione I.R.C.C.S.
Policlinico San Matteo
Pavia
Alfredo Falcone Azienda Ospedaliero
Universitaria Pisana
Pisa
Giacomo Allegrini Ospedale Felice Lotti
Pontedera
Pontedera
Samantha Di Donato Ospedale Santo Stefano Prato
Filippo Giovanardi Azienda USL di Reggio
Emilia
Ospedale di Guastalla
Reggio Emilia
Emiliano Tamburini Ospedale Infermi Rimini
Domenico Cristiano Corsi Ospedale San Giovanni
Calibita Fatebenefratelli
Isola Tiberina
Roma
Mario Roselli Policlinico Universitario
‘Tor Vergata’,
Roma
Enrico Cortesi Policlinico Umberto I Roma
Giuseppe Tonini Policlinico Unversitario
Campus Bio-Medico
Roma
Marco Benasso A.S.L. 2 Savonese Savona
Claudio Vergani Azienda Ospedaliera
Istituti Clinici di
Perfezionamento
Sesto S. Giovanni
Francesco Di Clemente Ospedali Riuniti della
Valdichiana Senese.
A.U.S.L. 7 Siena
Siena
Guido Francini Azienda Ospedaliera
Senese
Siena
Alessandro Bertolini Azienda Ospedaliera
della Valtellina e della
Valchiavenna
Sondrio
Francesco Leone Istituto di Candiolo I.R.C.C.S. Torino
Michela Frisinghelli Ospedale Civile Santa
Chiara
Trento
Adolfo Favaretto Azienda ULSS 9 Treviso
Ospedale Ca′ Foncello
Treviso
Nicoletta Pella A.O. Universitaria
Santa Maria della
Misericordia
Udine
Giampaolo Tortora Azienda Ospedaliera
Universitaria Integrata
Verona
Giuseppe Aprile Ospedale San Bortolo Vicenza
Enzo Maria Ruggeri Ospedale Belcolle Viterbo Viterbo
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Interventions
Patients considered eligible and who have signed a writ-
ten informed consent are randomly assigned to one of
the two treatment arms in a 1:1 ratio. Eligible patients
will be stratified according to age (≤75 versus > 75 years),
ECOG PS (0–1 versus 2) and G8 Score (≤14 versus >
14).
Arm A: FOLFOX plus panitumumab
Patients randomized to this arm receive FOLFOX-
panitumumab every 2 weeks up to 12 cycles with the
following schedule:
 Panitumumab 6 mg/kg iv over 60 min, day 1; if the
first infusion is tolerated, then subsequent infusions
may be administered over 30 to 60 min;
 Oxaliplatin 85 mg/sqm iv over 2 h, day 1;
 L-Leucovorin 200 mg/sqm iv over 2 h, day 1;
 5-fluoruracil 2400 mg/sqm 48 h-continuous
infusion, starting on day 1;
If no progression occurs, patients receive maintenance
panitumumab at the same dose used at the last cycle of the
induction treatment. Panitumumab is repeated biweekly
until disease progression, unacceptable toxicity or patient’s
refusal.
Arm B: 5-FU/LV plus panitumumab
Patients randomized to this arm receive 5FU-panitumumab
every 2 weeks up to 12 cycles with the following schedule:
 Panitumumab 6 mg/kg iv over 60 min, day 1; if the
first infusion is tolerated, then subsequent infusions
may be administered over 30 to 60 min;
 L-Leucovorin 200 mg/sqm iv over 2 h, day 1;
 5-fluoruracil 2400 mg/sqm 48 h-continuous
infusion, starting on day 1;
If no progression occurs, patients receive maintenance
panitumumab at the same dose used at the last cycle of
the induction treatment. Panitumumab is repeated bi-
weekly until disease progression, unacceptable toxicity
or patient’s refusal.
Disease assessment is performed every 8 weeks by
means of CT scan, according to RECIST 1.1 criteria.
Surgical radical resection of residual metastases in re-
sponsive patients is recommended and its feasibility should
be evaluated every 2 months. After resection, patients will
receive post-operative therapy up to 12 cycles of the same
chemotherapy regimen plus panitumumab received before
resection.
The second- and subsequent lines of treatment will be
based on investigators’ choice.
Statistical design
Assuming exponentially distributed event times, uniform
accrual over time, no loss to follow-up and an expected
Table 2 G8 Screening Tool
Items Possible Answers
A Has food intake declined over the past 3
months due to loss of appetite, digestive
problems, chewing or swallowing difficulties?
0: severe reduction in
food intake
1: moderate reduction
in food intake
2: normal food intake
B Weight loss during the last 3 months? 0: weight loss > 3 kg
1: does not know
2: weight loss between
1 and 3 kg
3: no weight loss
C Mobility 0: bed or chair bound
1: able to get out of
bed/chair but does
not go out
2: goes out
D Neuropsychological problems 0: severe dementia or
depression
1: mild dementia or
depression
2: no psychological
problems
F Body Mass Index (weight in
kg/height in m2)
0: BMI less than 19
1: BMI 19 to less than
21
2: BMI 21 to less than
23
3: BMI 23 or greater
G Takes more than 3 medications
per day
0: yes
1: no
H In comparison with other people of the
same age, how does the patient consider
his/her health status?
0: not as good
0,5: does not know
1: as good
2: better
I Age 0: > 85
1: 80–85
2: < 80
Table 3 CRASH Scoring System
Item Score
Diastolic Blood Pressure 0: ≤72 mmHg
1: > 72 mmHg
IADL 0 = 8
1: < 8
LDH 0: ≤ 0.74 x ULN
2: > 0.74 x ULN
ECOG PS 0: 0
1: 1–2
2: 3–4
MMS 0: 30;
2: < 30
MNA 0: 28–30
2: < 28
Chemotherapy risk (MAX2) 0: arm B (FU/LV + Pani)
1: arm A (FOLFOX+Pani)
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median PFS time equal to or greater than 9.65 months
with both experimental regimens, corresponding to a 6-
month PFS probability ≥65%, a sample size of 90 pa-
tients in each arm will guarantee to the study a power
equal to 90% for a one-sided Brookmeyer-Crowley test,
with a type I error rate equal to 5%, against the null of a
median PFS time equal to or less than 6 months.
The Kaplan-Meier approach will be used to estimate
median PFS for each treatment arm. The hypothesis test
will be conducted according to Brookmeyer-Crowley,
comparing the cumulative hazard estimate at 6 months
to the –log(0.50). No formal comparison between the re-
sults of the two treatment arms will be allowed.
All analyses of secondary endpoints will be descriptive
only and no formal statistical comparisons will be made
between the arms. Survival curves will be calculated ac-
cording to Kaplan–Meier methods. Log-rank tests strati-
fied by the same factors as used for randomization will
also be performed, as well as multivariable models in-
cluding all the significant baseline variables. The median
event times and corresponding 2-sided 95% CI for the
median will be provided.
The prognostic value of baseline G8 assessment for
predicting patients’ outcome will be investigated through
Cox proportional hazards model. The relationship be-
tween baseline data and patients’ survival will be graph-
ically investigated. The prognostic value of changes of
G8 score from baseline to disease progression will be
similarly investigated. The analyses will be adjusted for
known clinical prognostic factors. All analyses will be
adjusted for multiple testing.
The association of G8 score with clinical outcome will
be assessed in terms of the difference in OS in the two
groups of patients (score ≤ 14 versus > 14) by means of
log-rank test.
The association of CRASH score with toxicity will be
assessed comparing G3–4 adverse events in the four risk
categories (low, medium-low, medium-high and high
risk) by means of chi-square test.
Safety
All adverse events are recorded under the responsibility of
the investigator in the subjects’ medical records and in
electronic Case Report Forms (eCRFs), severity and rela-
tionship with the study treatment is assessed. Any medical
condition that at the judgment of the Investigator may
affect patients’ safety is a possible reason for treatment
discontinuation.
An adverse event with the following characteristics:
fatal, life threatening, requiring in-patient hospitalization
or prolongation of existing hospitalization; resulting in
persistent or significant disability/incapacity; congenital
anomaly/birth defect or other significant medical hazard
is defined as serious adverse event (SAE) and must be
reported to the coordinating center within 24 h from its
occurrence. The investigator should notify the Sponsor
of all SAEs in accordance with local procedures, statutes
and the European Clinical Trial Directive (where applic-
able). The Sponsor is responsible for the medical review
of all SAEs and for their notification to the appropriate
Ethics Committees, Competent Authorities and partici-
pating Investigators, in accordance with local require-
ments and the European Clinical Trial Directive.
Data monitoring and quality assurance
Each participating Investigator is responsible for ensur-
ing data quality as planned in the Data Validation Plan
document. The coordinating Data Center is responsible
of monitoring visits at the participating centers in order
to verify consistency, completeness and accuracy of data
and periodically issues Data Query Forms in case of in-
consistent data. Investigators guarantee that all persons
involved in this study respect the confidentiality of any
information concerning the trial subject.
Study schedule
The trial has started on July 2016. Study length is
planned to be about 36 months, with an enrollment
period of about 24 months and a minimum period of
follow-up of 12 months. The estimated study completion
date is July 2019 (final data collection date for primary
outcome measure). Survival status will be collected until
patients’ death.
Coordination
Istituto Oncologico Veneto IOV-IRCCS is responsible
for the overall coordination and management of the
study on behalf of Gruppo Oncologico Nord-Ovest
(G.O.N.O.) Cooperative Group.
Ethics and regulatory considerations
This study is conducted in accordance with globally ac-
cepted standards of Good Clinical Practice and the latest
version of the Declaration of Helsinki, and in agreement
with local law(s) and regulation(s).
The study (Protocol version 2.2, April 18th 2016) was
approved for all participating centers by AIFA, the Italian
health authority (Agenzia Italiana del Farmaco) on May
23rd 2016 and registered on September 3rd 2015 at
EudraCT database (EudraCT 2015–003888-10) and on
July 11th 2016 at Clinicaltrials.gov (NCT02904031). Docu-
mented approval from appropriate IEC(s)/IRB(s) have
been obtained for all participating centers before the start
of the study.
Gruppo Oncologico Nord-Ovest (G.O.N.O.) Coopera-
tive Group signed an insurance policy with the Company
QBE Insurance to provide patients with compensation for
Battaglin et al. BMC Cancer  (2018) 18:98 Page 8 of 11
any injury associated with administration of the study
drugs and other aspects of the conduct of the trial.
In case of important protocol modifications (i.e. changes
to eligibility criteria, outcomes, analysis) all necessary exten-
sions, amendments and/or renewal will be notified to the
IEC/IRB for approval and will be forwarded to the Sponsor.
All candidate patients provide their informed consent
to study procedures before enrollment in the study. In-
vestigators are responsible for informing each patient (or
legally authorized representative) of the nature of the
study, its purpose, the procedures involved, the expected
duration, the potential risks and benefits involved and
any discomfort it may entail.
Discussion
Based on available data, fluoropyrimidine-based mono-
therapy plus bevacizumab is currently considered a stand-
ard upfront treatment for elderly mCRC patients,
irrespectively of RAS status. To date, data on treatment of
elderly patients with chemotherapy plus anti-EGFRs are
scarce and rely on retrospective or non-randomized stud-
ies. While FOLFOX plus panitumumab is a standard first-
line option for RAS wild-type mCRC, evidences about the
combination of an anti-EGFR with a fluoropyrimidine-
based monotherapy are lacking. The PANDA study aims
at exploring the safety and efficacy of panitumumab in
combination with FOLFOX or with 5-FU/LV in selected
elderly patients with centrally-confirmed RAS and BRAF
wild-type mCRC. The choice of a maintenance strategy
with panitumumab monotherapy after an induction with
chemotherapy plus panitumumab is based on recent lit-
erature evidences suggesting that maintenance therapy
with single-agent anti-EGFR following chemotherapy plus
anti-EGFR is not inferior to continuing treatment with
chemotherapy plus anti-EGFR [25]. This strategy seems to
be a reasonable option in a molecularly selected popula-
tion of elderly patients in order to improve treatment tol-
erance and toxicity profile. The results of the present trial
will help in driving further developments of one of the
two combinations under study. Moreover, taking into ac-
count the complexity of clinical evaluation and treatment
choices in elderly patients, geriatric assessment by means
of G8 and CRASH score, two well renowned geriatric
screening tools, has been integrated in the protocol proce-
dures in order to ensure a comprehensive evaluation of
patients before treatment start. The study will prospect-
ively evaluate the association of these scores with clinical
outcome and treatment-related severe toxicity, thus hope-
fully providing additional evidences for the use of these
tools in everyday clinical practice to optimize cancer treat-
ment of elderly patients.
Additionally, we expect that enrolling patients in the
trial and performing RAS/BRAF testing in the study
population will additionally give a more extensive view
of the mutational incidence in this selected subset of pa-
tients in a real-life setting, improving our knowledge of
the disease. At the same time, the collection of archival
tissue alongside biological samples (blood and urine),
which is planned as part of the study procedures, will
contribute to create a valuable source for future analyses
and research in this specific population.
Recently, primary tumor sidedness has emerged as a
novel potential surrogate predictive marker for mCRCs
treated with anti-EGFRs. Retrospective data from sub-
group analyses of large randomized phase III trials pre-
sented in 2016 at the ASCO Annual Meeting and at the
ESMO Congress, in fact, supported the evidence of a
lack of benefit from anti-EGFR treatment in right-sided
tumors. Conversely, patients with left-sided tumors
showed better survival outcomes and treatment benefit
from anti-EGFR therapies. These data have subsequently
been confirmed by two large meta-analyses showing a
significant benefit from first-line anti-EGFR treatment in
RAS wild-type left-sided tumors opposite to right-sided
ones [26, 27]. Despite the limitations of these unplanned
retrospective subgroup analyses, data are consistent
across several randomized trials, and support the ration-
ale of avoiding anti-EGFRs in the first-line treatment for
right-sided mCRCs when other options are available.
Nevertheless, this evidence has not been prospectively
validated and at the time of the design of our trial this
topic was not under debate yet, thus primary tumor
sidedness is not considered among inclusion/exclusion
criteria. Data on primary tumor location are being col-
lected in the study population and future analyses will
help to further address this issue.
Additional observational studies are planned by our
Institution to collect data on real life application of geri-
atric screening tools and efficacy/safety profile of com-
bined treatment in elderly patients, and will integrate
the current effort in defining the optimal treatment
strategy for these patients [28].
In conclusion, results of our trial combined with those
of other studies exploring different treatment combina-
tions in a similar population (i.e. XELOX plus bevacizu-
mab) [29] will contribute to create a body of evidences
to better understand clinical and molecular features of
mCRC in the elderly and guide clinical and therapeutic
decisions in this complex setting.
Abbreviations
5-FU: 5-fluorouracil; AIFA: Agenzia Italiana del Farmaco; BRAF: V-Raf murine
sarcoma viral oncogene homolog B1; CAPOX/XELOX: Capecitabine,
Oxaliplatin; CI: Confidence Interval; ECOG PS: Eastern Cooperative Oncology
Group – performance status; eCRFs: electronic Case Report Forms;
EGFR: Epidermal Growth Factor Receptor; ETS: Early tumor shrinkage;
FOLFOX: Folinic-acid, 5-Fluorouracil, Oxaliplatin; G.O.N.O.: Gruppo Oncologico
Nord-Ovest; HR: Hazard Ratio; IADLs: Instrumental Activities of Daily Living;
LV: leucovorin; mCRC: metastatic Colorectal Cancer; MMSE: Mini Mental State
Exam; NCI CTCAE: National Cancer Institute Common Terminology Criteria
for Adverse Events; ORR: Overall Response Rate; OS: Overall Survival;
Battaglin et al. BMC Cancer  (2018) 18:98 Page 9 of 11
OTR: Overall Toxicity Rate; PFS: Progression Free Survival; RAS: Rat sarcoma
viral oncogene homolog; RECIST: Response Evaluation Criteria in Solid
Tumors; SAE: Serious Adverse Event
Acknowledgements
Not applicable
Funding
The present study is an investigator-initiated trial, carried out by participating
clinicians, who have the intellectual ownership of the results. The study is
sponsored by Gruppo Oncologico Nord-Ovest (G.O.N.O.) Cooperative Group
Via G. Mameli, 3 – Genoa (Italy).
Availability of data and materials
Not applicable
Protocol version and Date and version identifier
Version 2.2, April 18th 2016.
Use of copyright protected materials
Not applicable
Authors’ contributions
FL and SL participated in the design of the study and wrote the original
protocol for the study. FB, MS and FB drafted the manuscript. All authors
directly provided their contribution, read and approved the final manuscript.
Ethics approval and consent to participate
The trial was approved by the Ethics Committee of the Istituto Oncologico
Veneto IRCCS and by local Committees of participating centers. All study
participants will provide their written informed consent after careful
explanation by their treating investigators.
Consent for publication
Not applicable
Competing interests
Fotios Loupakis is an advisor/speaker for Amgen Inc., Bayer Healthcare, Eli
Lilly and Company and Roche. Sara Lonardi is an advisor/speaker for Amgen
Inc., Bayer Healthcare, Eli Lilly and Company, Roche and Sanofi. Filippo
Pietrantonio has advisory role/honoraria for Amgen Inc., Roche, Sanofi, Eli
Lilly and Company and Bayer Healthcare. Mario Scartozzi is an advisor/
speaker for Merck-Serono, Bristol-Myers Squibb, Amgen Inc., Bayer Healthcare,
Eli Lilly and Company and Sanofi-Aventis.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Istituto Oncologico Veneto - IRCCS, S.C. Oncologia Medica 1, Dipartimento
di Oncologia Clinica e Sperimentale, Via Gattamelata, 64, 35128 Padova, Italy.
2Fondazione IRCCS Istituto Nazionale Tumori, Dipartimento di Oncologia
Medica, Via Venezian, 1, 20133 Milan, Italy. 3Azienda Unita Locale
Socio-Sanitaria N°3 Serenissima – Distretto Mirano, Dolo, Noale –
Dipartimento di Scienze Mediche, U.O.C. Oncologia ed Ematologia
Oncologica, Via Don G. Sartor, 4, 30035 Mirano, VE, Italy. 4Policlinico
Universitario Campus Bio-Medico, U.O.C. Oncologia Medica, Via Alvaro del
Portillo, 200, 00128 Rome, Italy. 5Ospedale Senatore A. Perrino, U.O.C.
Oncologia Medica, Strada Statale 7 (Appia), 72100 Brindisi, Italy. 6U.O.
Oncologia Medica, Dipartimento di Medicina, Ospedale Universitario
Policlinico Tor Vergata, Università degli Studi di Roma Tor Vergata, Viale
Oxford, 81, 00133 Rome, Italy. 7Oncologia, Azienda Ospedaliera Universitaria
Integrata di Verona, Piazzale Scuro, 10, 37134 Verona, Italy. 8IRCCS Istituto
Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), U.O.
Oncologia Medica, Via P. Maroncelli, 40, 47014 Meldola, FC, Italy. 9Azienda
Ospedaliero Universitaria Pisana, U.O. Oncologia Medica 2 Universitaria, Via
Roma, 67, 56126 Pisa, Italy. 10ASST Papa Giovanni XXIII, U.O. Oncologia
Medica, Piazza OMS, 1, 24127 Bergamo, Italy. 11U.O. Oncologia Medica,
Azienda Ospedaliero-Universitaria di Cagliari e Università di Cagliari, via
Ospedale, 54, 09124 Cagliari, Italy. 12Azienda Sanitaria Universitaria Integrata
di Udine, Dipartimento di Oncologia, Piazzale Santa Maria della Misericordia,
15, 33100 Udine, Italy. 13Centro Coordinamento Sperimentazioni Cliniche –
Istituto Toscano Tumori, Via Taddeo Alderotti, 26/N, 50139 Florence, Italy.
Received: 14 September 2017 Accepted: 17 January 2018
References
1. Siegel RL, Miller KD, Fedewa SA, et al. Colorectal cancer statistics, 2017. CA
Cancer J Clin. 2017 May 6;67(3):177–93.
2. NJ MC, Dotan E, Browner I. Refining the chemotherapy approach for older
patients with colon cancer. J Clin Oncol. 2014;32:2570–80.
3. Sorbye H, Pfeiffer P, Cavalli-Bjorkman N, et al. Clinical trial enrollment,
patient characteristics, and survival differences in prospectively registered
metastatic colorectal cancer patients. Cancer. 2009;115:4679–87.
4. Papamichael D, Audisio RA, Glimelius B, et al. Treatment of colorectal cancer
in older patients: International Society of Geriatric Oncology (SIOG)
consensus recommendations 2013. Ann Oncol. 2015;26:463–76.
5. Cunningham D, Lang I, Marcuello E, et al. Bevacizumab plus capecitabine
versus capecitabine alone in elderly patients with previously untreated
metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial.
Lancet Oncol. 2013;14:1077–85.
6. Seymour MT, Thompson LC, Wasan HS, et al. Chemotherapy options in
elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2):
an open-label, randomised factorial trial. Lancet. 2011;377:1749–59.
7. Aparicio T, Jouve JL, Teillet L, et al. Geriatric factors predict chemotherapy
feasibility: ancillary results of FFCD 2001-02 phase III study in first-line
chemotherapy for metastatic colorectal cancer in elderly patients. J Clin
Oncol. 2013;31:1464–70.
8. Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for
the management of patients with metastatic colorectal cancer. Ann Oncol.
2016;27:1386–422.
9. National Comprehensive Cancer Network. Clinical practice guidelines in
oncology. Colon cancer. Version 1.2017. Avalable at. https://www.nccn.org/
professionals/physician_gls/pdf/colon.pdf [Last accessed 15 Oct 2017
10. Allegra CJ, Rumble RB, Hamilton SR, et al. Extended RAS gene mutation
testing in metastatic colorectal carcinoma to predict response to anti-
epidermal growth factor receptor monoclonal antibody therapy: American
Society of Clinical Oncology provisional clinical opinion update 2015. J Clin
Oncol. 2016;34:179–85.
11. Rowland A, Dias MM, Wiese MD, et al. Meta-analysis of BRAF mutation as a
predictive biomarker of benefit from anti-EGFR monoclonal antibody
therapy for RAS wild-type metastatic colorectal cancer. Br J Cancer. 2015;
112:1888–94.
12. Pietrantonio F, Petrelli F, Coinu A, et al. Predictive role of BRAF mutations in
patients with advanced colorectal cancer receiving cetuximab and
panitumumab: a meta-analysis. Eur J Cancer. 2015;51:587–94.
13. EMJ VB, de Boer A, Beijnen JH, JHM S. BRAF mutations as predictive biomarker for
response to anti-EGFR monoclonal antibodies. Oncologist. 2017;22(7):864–72.
14. Douillard JY, Oliner KS, Siena S, et al. Panitumumab-FOLFOX4 treatment and
RAS mutations in colorectal cancer. N Engl J Med. 2013;369:1023–34.
15. Douillard JY, Siena S, Peeters M, et al. Impact of baseline age on efficacy
and safety of first-line panitumumab (pmab) + FOLFOX4 vs FOLFOX4
treatment. Ann Oncol. 2014;25(Suppl 4):iv167–209. https://doi.org/10.1093/
annonc/mdu333.
16. Sastre J, Massuti B, Pulido G, et al. First-line single-agent panitumumab in
frail elderly patients with wild-type KRAS metastatic colorectal cancer and
poor prognostic factors: a phase II study of the Spanish cooperative Group
for the Treatment of digestive Tumours. Eur J Cancer. 2015;51:1371–80.
17. Pietrantonio F, Cremolini C, Aprile G, et al. Single-agent Panitumumab in
frail elderly patients with advanced RAS and BRAF wild-type colorectal
cancer: challenging drug label to light up new hope. Oncologist. 2015;
20(11):1261–5.
18. Bellera CA, Rainfray M, Mathoulin-Pelissier S, et al. Screening older cancer
patients: first evaluation of the G-8 geriatric screening tool. Ann Oncol.
2012;23:2166–72.
19. Liuu E, Canoui-Poitrine F, Tournigand C. External validation of the G8
geriatric screening tool to identify vulnerable elderly cancer patients: the
ELCAPA-02 study [abstract]. J Geriatr Oncol. 2012;3(Suppl 45):P23.
20. Kenis C, Decoster L, Van Puyvelde K, et al. Performance of two geriatric
screening tools in older patients with cancer. J Clin Oncol. 2014;32:19–26.
Battaglin et al. BMC Cancer  (2018) 18:98 Page 10 of 11
21. Extermann M, Boler I, Reich RR, et al. Predicting the risk of chemotherapy
toxicity in older patients: the chemotherapy risk assessment scale for high-
age patients (CRASH) score. Cancer. 2012;118:3377–86.
22. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in
solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.
23. https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_
5x7.pdf. Accessed 24 Aug 2017.
24. http://eforms.moffitt.org/crashscore.aspx. Accessed 24 Aug 2017.
25. García Alfonso P, Benavides M, Ruiz AS, et al. Phase II study of first-line
mFOLFOX plus cetuximab (C) for 8 cycles followed by mFOLFOX plus C or
single agent (s/a) C as maintenance therapy in patients (p) with metastatic
colorectal cancer (mCRC): the MACRO-2 trial (Spanish cooperative Group for
the Treatment of digestive tumors [TTD]). Ann Oncol. 2014;25(Suppl 4):iv167.
26. Holch JW, Ricard I, Stintzing S, et al. The relevance of primary tumour
location in patients with metastatic colorectal cancer: a meta-analysis of
first-line clinical trials. Eur J Cancer. 2017;70:87–98.
27. Arnold D, Lueza B, Douillard JY et al. Prognostic and predictive value of
primary tumour side in patients with RAS wild-type metastatic colorectal
cancer treated with chemotherapy and EGFR directed antibodies in six
randomised trials. Ann Oncol. 2017;28(8):1713–729. https://doi.org/10.1093/
annonc/mdx175.
28. The COBRA Study. EU Clinical Trials Register. EudraCT identifier. 2017;2017-
002207-98.
29. Feliu J, Salud A, Safont MJ, et al. First-line bevacizumab and capecitabine-
oxaliplatin in elderly patients with mCRC: GEMCAD phase II BECOX study. Br
J Cancer. 2014;111(2):241–8.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Battaglin et al. BMC Cancer  (2018) 18:98 Page 11 of 11
